Last reviewed · How we verify
Placebo eugonadal
Placebo eugonadal is an inert control substance used in clinical research to maintain normal testosterone levels as a comparator in hormone studies.
Placebo eugonadal is an inert control substance used in clinical research to maintain normal testosterone levels as a comparator in hormone studies. Used for Control arm in clinical trials of testosterone replacement therapy or gonadal hormone studies.
At a glance
| Generic name | Placebo eugonadal |
|---|---|
| Sponsor | Medical University of Graz |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
As a placebo formulation, it contains no active pharmaceutical ingredient and serves as a control arm in clinical trials investigating gonadal hormone replacement or testosterone therapy. The term 'eugonadal' indicates the study population maintains normal gonadal function, allowing researchers to isolate the effects of active interventions from baseline hormonal status.
Approved indications
- Control arm in clinical trials of testosterone replacement therapy or gonadal hormone studies
Common side effects
Key clinical trials
- Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism (NA)
- Testosterone Replacement in Men With Diabetes and Obesity (PHASE4)
- Hypogonadism in Young Men With Type 2 Diabetes (PHASE2)
- Vitamin D Treatment and Hypogonadism in Men (PHASE4)
- TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST (PHASE4)
- Effect of Pioglitazone on Testosterone in Eugonadal Men With Type 2 Diabetes Mellitus - A Pilot Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo eugonadal CI brief — competitive landscape report
- Placebo eugonadal updates RSS · CI watch RSS
- Medical University of Graz portfolio CI